ABSTRACT
INTRODUCTION: Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm and it can originate from the conjunctiva and/ or corneal epithelium. Since the rate of recurrence after surgical excision is high, chemotherapeutic and immunotherapeutic agents such as interferon alpha-2b (IFN α-2b) have been used for its treatment. OBJECTIVE: Our objective is to describe the demographic variables of patients with OSSN treated with IFN α-2b and to describe the outcomes of its use in Mexican patients, treated between 2011 and 2017 at Instituto de Oftalmología Fundación Conde de Valenciana. MATERIALS AND METHODS: This is a non-randomized retrospective interventional case series. We reviewed the files of patients older than 18 years, with clinical and/or histopathological diagnosis of OSSN, treated with IFN α-2b alone or in combination with surgery, with a minimum of 6 months follow-up. We studied demographic variables, such as gender, age, eye affected and associated risks factors; we also studied the type of therapy with interferon (topical, intralesional and/or associated with surgery), time of treatment, time of follow up, recurrences and complications. RESULTS: A total of 39 patients were included. The mean age of diagnosis was 61 ± 16 years and OSSN was more frequent in males (64.1% of cases). Most of the cases (43.6%) had no identifiable risk factors. The mean time of IFN α-2b treatment was 5 ± 2 months, being higher in the intralesional group (6.5 months) than in the topical group (4.2 months). The clinical resolution with the use of IFN α-2b was evidenced between 0.5 and 10 months, being achieved in 87.1% of the patients. CONCLUSIONS: The use of IFN α-2b is effective for the treatment of OSSN with a high success rate (87.1%) and a low incidence of relapse (5 cases), with no reported complications during follow up.
Subject(s)
Carcinoma, Squamous Cell/drug therapy , Eye Neoplasms/drug therapy , Interferon alpha-2/administration & dosage , Administration, Topical , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Carcinoma, Squamous Cell/diagnosis , Conjunctiva/pathology , Dose-Response Relationship, Drug , Epithelium, Corneal/pathology , Eye Neoplasms/pathology , Female , Humans , Injections, Intralesional , Male , Middle Aged , Ophthalmic Solutions/administration & dosage , Retrospective Studies , Treatment Outcome , Young AdultABSTRACT
Establecer las causas involucradas y las características clínicas distintivas en la aparición del síndrome del vértice orbitario. Se hizo una evaluación observacional, retrospectiva y transversal de historias clínicas de 55 pacientes que acudieron a consulta de neuro-oftalmología durante el período de julio de 1980 a julio de 2000. La edad promedio fue de 38,2 años (DE 18,8) con rango de 2 a 80 años y 50,91 por ciento de los pacientes fueron del sexo femenino (28 pacientes). El síndrome debutó de forma bimodal con 61,11 por ciento de forma monosintomática y 38,89 por ciento de forma polisintomática. Los síntomas más comunes fueron disminución de la agudeza visual (77,78 por ciento), dolor en la distribución de la rama oftálmica del trigémino (66,67 por ciento) y proptosis (46,30 por ciento). Clínicamente se evidenció neuropatía óptica (84,45 por ciento), proptosis (85,45 por ciento) y oftalmoplejía (89,09 por ciento). En el 80 por ciento de los pacientes el síndrome se manifestó de manera incompleta. Las causas responsables fueron neoplasias (56,36 por ciento), patología inflamatoria no infecciosa (20 por ciento), traumatismos (10,91 por ciento), vasculogénicas (7,27 por ciento) e inflamatorias infecciosas (3,64 por ciento). El síndrome de vértice orbitario se presenta con características clínicas precisas y alta asociación a procesos neoplásicos
